William Proctor Harris

7.6k total citations · 2 hit papers
88 papers, 3.1k citations indexed

About

William Proctor Harris is a scholar working on Oncology, Hepatology and Surgery. According to data from OpenAlex, William Proctor Harris has authored 88 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 35 papers in Hepatology and 27 papers in Surgery. Recurrent topics in William Proctor Harris's work include Hepatocellular Carcinoma Treatment and Prognosis (34 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (21 papers) and Pancreatic and Hepatic Oncology Research (20 papers). William Proctor Harris is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (34 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (21 papers) and Pancreatic and Hepatic Oncology Research (20 papers). William Proctor Harris collaborates with scholars based in United States, Italy and United Kingdom. William Proctor Harris's co-authors include Peter S. Nelson, Elahe A. Mostaghel, Bruce Montgomery, Sunil R. Hingorani, Sharon W. Kwan, Wen-wai Yim, Meliha Yetişgen, Ping Jiang, Fadi Braiteh and Andrew L. Coveler and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

William Proctor Harris

83 papers receiving 3.1k citations

Hit Papers

Androgen deprivation therapy: progress in understanding m... 2009 2026 2014 2020 2009 2017 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
    2009 675 citations William Proctor Harris et al. profile →
  2. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
    2017 365 citations Sunil R. Hingorani, Lei Zheng et al. Journal of Clinical Oncology profile →

Peers

William Proctor Harris
Renuka Iyer United States
John Kauh United States
Erika Martinelli Italy
Hirofumi Akita Japan
Petr Kavan Canada
John H. Strickler United States
Herbert H. Loong Hong Kong
Enrico Vasile Italy
Kabir Mody United States
Fabiana Tatangelo Italy
Renuka Iyer United States
William Proctor Harris
Citations per year, relative to William Proctor Harris William Proctor Harris (= 1×) peers Renuka Iyer

Countries citing papers authored by William Proctor Harris

Since Specialization
Citations

This map shows the geographic impact of William Proctor Harris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Proctor Harris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Proctor Harris more than expected).

Fields of papers citing papers by William Proctor Harris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Proctor Harris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Proctor Harris. The network helps show where William Proctor Harris may publish in the future.

Co-authorship network of co-authors of William Proctor Harris

This figure shows the co-authorship network connecting the top 25 collaborators of William Proctor Harris. A scholar is included among the top collaborators of William Proctor Harris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Proctor Harris. William Proctor Harris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yu, Shawn, Menggang Yu, David Mauro, et al.. (2024). A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma. The Oncologist. 29(3). 270–e413. 20 indexed citations
3.
King, Gentry Teng, R J Berg, Melissa C. Stoppler, et al.. (2024). Genomic and immune landscape of biliary tract cancers with ARID1A, PBRM1, and BAP1 alterations.. Journal of Clinical Oncology. 42(3_suppl). 557–557. 1 indexed citations
4.
King, Gentry Teng, Stacey A. Cohen, E. Gabriela Chiorean, et al.. (2023). 114P Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers. Annals of Oncology. 34. S225–S225. 4 indexed citations
5.
6.
Huang, Hsuan‐Ying, Chien‐Feng Li, Yung‐Ming Jeng, et al.. (2021). S100P as a marker for poor survival and advanced stage in gallbladder carcinoma. Annals of Diagnostic Pathology. 52. 151736–151736. 4 indexed citations
7.
Galle, Peter R., Max W. Sung, William Proctor Harris, et al.. (2020). 990P Updated results of a phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). Annals of Oncology. 31. S691–S692. 9 indexed citations
8.
9.
Harris, William Proctor, Kit Man Wong, Supriya K. Saha, Imane El Dika, & Ghassan K. Abou‐Alfa. (2018). Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers. Seminars in Oncology. 45(3). 116–123. 9 indexed citations
10.
Hingorani, Sunil R., Lei Zheng, Andrea J. Bullock, et al.. (2017). HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. Journal of Clinical Oncology. 36(4). 359–366. 365 indexed citations breakdown →
11.
Hingorani, Sunil R., Andrea J. Bullock, Tara Elisabeth Seery, et al.. (2017). Randomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA). Annals of Oncology. 28. v261–v261. 4 indexed citations
12.
Hingorani, Sunil R., Andrea J. Bullock, Tara Elisabeth Seery, et al.. (2017). PEGPH20 improves pfs in patients with metastatic pancreatic ductal adenocarcinoma: A randomized phase 2 study in combination with nab-paclitaxel/gemcitabine. Annals of Oncology. 28. iii137–iii138. 5 indexed citations
13.
Rimassa, Lorenza, María Reig, Giovanni Abbadessa, et al.. (2017). Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. World Journal of Gastroenterology. 23(13). 2448–2448. 10 indexed citations
14.
Chapman, Tobias R., Stephen R. Bowen, Stephanie K. Schaub, et al.. (2017). Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: Defining clinically relevant endpoints. Practical Radiation Oncology. 8(3). 157–166. 23 indexed citations
15.
Hingorani, Sunil R., William Proctor Harris, J. Thaddeus Beck, et al.. (2016). Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Clinical Cancer Research. 22(12). 2848–2854. 262 indexed citations
16.
17.
Mazzaferro, Vincenzo, Walid L. Shaib, Lorenza Rimassa, et al.. (2016). PD-019 ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA). Annals of Oncology. 27. ii109–ii109. 9 indexed citations
18.
Lawson, Michelle A., Julia Paton‐Hough, Holly Evans, et al.. (2015). NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease. PLoS ONE. 10(3). e0119546–e0119546. 29 indexed citations
19.
James, Andrew, Jason Izard, William Proctor Harris, et al.. (2014). Role of Maximal Endoscopic Resection Before Cystectomy for Invasive Urothelial Bladder Cancer. Clinical Genitourinary Cancer. 12(4). 287–291. 18 indexed citations
20.
Huang, Shiew‐Mei, Thomas B. Marriott, Howard Weintraub, et al.. (1988). Single-dose and multiple-dose pharmacokinetics of etintidine in healthy volunteers. European Journal of Clinical Pharmacology. 34(1). 101–104. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Renuka Iyer Breakdown of academic impact, for papers by John Kauh Breakdown of academic impact, for papers by Erika Martinelli Breakdown of academic impact, for papers by Hirofumi Akita Breakdown of academic impact, for papers by Petr Kavan Breakdown of academic impact, for papers by John H. Strickler Breakdown of academic impact, for papers by Herbert H. Loong Breakdown of academic impact, for papers by Enrico Vasile Breakdown of academic impact, for papers by Kabir Mody Breakdown of academic impact, for papers by Fabiana Tatangelo
Rankless by CCL
2026